| Primary | Responder in Disability Assessment Scale (DAS) at Week 4 - Per Protocol Set | The primary efficacy endpoint is the number of responder at Week 4; response defined as an improvement (reduction) of at least one point in the DAS for the primary therapeutic target from baseline visit to Week 4. The DAS determines the functional impairment for the domains hygiene, dressing, limb position and pain according to the following scale: 0 = no disability; 1 = mild disability; 2 = moderate disability; 3 = severe disability. At Screening visit, the subject and investigator, selected together one of the four domains as the primary therapeutic target. | Analysis is based on Per Protocol Set, defined as all randomized subjects who received at least one dose of study drug and who have no major deviation from study protocol. For this set of subjects no missing values can occur for the primary endpoint. | Posted | | Number | | participants | | At week 4 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| | | Title | Denominators | Categories |
|---|
| | |
| | Group IDs | Group Description | Statistical Method | Statistical Comment | P-Value | P-Value Comment | Parameter Type | Parameter Value | Dispersion Type | Dispersion Value | Confidence Interval Sides | Confidence Interval % | CI Lower Limit | CI Upper Limit | CI Lower Limit Comment | CI Upper Limit Comment | Estimate Comment | Tested Non-Inferiority | Non-Inferiority Type | Non-Inferiority Comment | Other Analysis Description |
|---|
| Null hypothesis: The response rate for the low volume dilution group (50 U/ml) is greater than the response rate for the high volume dilution group (20 U/ml). | | | | | difference in response rates | 10.6 | | | 2-Sided | 95 | -4.4 | 24.9 | | | difference in response rates = response rate for high volume dilution group (20 U/ml) - response rate for low volume dilution group (50 U/ml) | Yes | Non-Inferiority or Equivalence | A two-sided 95% Newcombe-Wilson confidence interval for the difference between the response rates of the groups was calculated. The lower bound of the Newcombe-Wilson CI for the difference of proportions was compared to the non-inferiority margin of -25%. |
|
| Secondary | Responder in DAS at Week 4 - Full Analysis Set | Response is defined as an improvement (reduction) of at least one point in the DAS for the primary therapeutic target from baseline visit. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | week 4 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Responder in DAS at Week 12 - Full Analysis Set | Response is defined as an improvement (reduction) of at least one point in the DAS for the primary therapeutic target from baseline visit. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | week 12 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Responder in DAS at Follow up - Full Analysis Set | Response is defined as an improvement (reduction) of at least one point in the DAS for the primary therapeutic target from baseline visit. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | follow up visit, between week 12 and week 20 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Responder in Frenchay Arm Test (FAT) at Week 4 - Full Analysis Set | Response is defined as an improvement (increase) of at least one point in the FAT from baseline visit. For the FAT the investigator assessed the extent of functionality of the upper limb according to five standardized tests. Each test is rated with 0 = failed or 1 = successfully passed. For the evaluation, the sum of all test scores was calculated resulting in a total score from 0 to 5. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | Week 4 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Responder in FAT at Week 12 - Full Analysis Set | Response is defined as an improvement (increase) of at least one point in the FAT from baseline visit. For the FAT the investigator assessed the extent of functionality of the upper limb according to five standardized tests. Each test is rated with 0 = failed or 1 = successfully passed. For the evaluation, the sum of all test scores was calculated resulting in a total score from 0 to 5. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | Week 12 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Responder in FAT at Follow up - Full Analysis Set | Response is defined as an improvement (increase) of at least one point in the FAT from baseline visit. For the FAT the investigator assessed the extent of functionality of the upper limb according to five standardized tests. Each test is rated with 0 = failed or 1 = successfully passed. For the evaluation, the sum of all test scores was calculated resulting in a total score from 0 to 5. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | follow up visit, between week 12 and week 20 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Responder in Ashworth Scale (Elbow Flexors) at Week 4 - Full Analysis Set | Response is defined as an improvement of at least one point in the Ashworth Scale for the treated muscle group from baseline visit. The Ashworth Scale is a 5-point-scale to rate to degree of spasticity: 0 = No increase in tone; 1 = Slight increase in tone giving a "catch" when the limb was moved in flexion or extension; 2 = More marked increase in tone, but limb easily flexed; 3 = Considerable increase in tone - passive movements difficult; 4 = Limb rigid in flexion or extension. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | week 4 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Responder in Ashworth Scale (Elbow Flexors) at Week 12 - Full Analysis Set | Response is defined as an improvement of at least one point in the Ashworth Scale for the treated muscle group from baseline visit. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | week 12 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Responder in Ashworth Scale (Elbow Flexors) at Follow up - Full Analysis Set | Response is defined as an improvement of at least one point in the Ashworth Scale for the treated muscle group from baseline visit. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | follow up visit, between week 12 and week 20 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Responder in Ashworth Scale (Wrist Flexors) at Week 4 - Full Analysis Set | Response is defined as an improvement of at least one point in the Ashworth Scale for the treated muscle group from baseline visit. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | week 4 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Responder in Ashworth Scale (Wrist Flexors) at Week 12 - Full Analysis Set | Response is defined as an improvement of at least one point in the Ashworth Scale for the treated muscle group from baseline visit. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | week 12 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Responder in Ashworth Scale (Wrist Flexors) at Follow up - Full Analysis Set | Response is defined as an improvement of at least one point in the Ashworth Scale for the treated muscle group from baseline visit. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | follow up visit, between week 12 and week 20 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Responder in Ashworth Scale (Thumb Flexors) at Week 4 - Full Analysis Set | Response is defined as an improvement of at least one point in the Ashworth Scale for the treated muscle group from baseline visit. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | week 4 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Responder in Ashworth Scale (Thumb Flexors) at Week 12 - Full Analysis Set | Response is defined as an improvement of at least one point in the Ashworth Scale for the treated muscle group from baseline visit. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | week 12 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Responder in Ashworth Scale (Thumb Flexors) at Follow up - Full Analysis Set | Response is defined as an improvement of at least one point in the Ashworth Scale for the treated muscle group from baseline visit. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | follow up visit, between week 12 and week 20 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Responder in Ashworth Scale (Fingers Flexors) at Week 4 - Full Analysis Set | Response is defined as an improvement of at least one point in the Ashworth Scale for the treated muscle group from baseline visit. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | week 4 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Responder in Ashworth Scale (Fingers Flexors) at Week 12 - Full Analysis Set | Response is defined as an improvement of at least one point in the Ashworth Scale for the treated muscle group from baseline visit. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | week 12 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Responder in Ashworth Scale (Fingers Flexors) at Follow up - Full Analysis Set | Response is defined as an improvement of at least one point in the Ashworth Scale for the treated muscle group from baseline visit. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | follow up visit, between week 12 and week 20 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Responder in Ashworth Scale (Forearm Pronators) at Week 4 - Full Analysis Set | Response is defined as an improvement of at least one point in the Ashworth Scale for the treated muscle group from baseline visit. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | week 4 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Responder in Ashworth Scale (Forearm Pronators) at Week 12 - Full Analysis Set | Response is defined as an improvement of at least one point in the Ashworth Scale for the treated muscle group from baseline visit. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | week 12 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Responder in Ashworth Scale (Forearm Pronators) at Follow up - Full Analysis Set | Response is defined as an improvement of at least one point in the Ashworth Scale for the treated muscle group from baseline visit. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | follow up visit, between week 12 and week 20 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Change From Baseline in Passive Range of Motion (PROM) - Wrist Extension | For the PROM all motions of wrist and elbow were measured from a defined neutral starting point position. The degrees of motion were added in the direction the wrist and elbow moved from the neutral starting position. The neutral starting position was the position of an upright standing/sitting person. The angle of the motion from the neutral starting position was measured in degrees using a goniometer. Angles were measured for the wrist with maximal dorsal extension, neutral position and maximal palmar flexion, and for the elbow with maximal extension, neutral position and maximal flexion. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Mean | Standard Error | degree | | baseline, week 4, week 12, follow up (between week 12 and week 20) | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Change From Baseline in Passive Range of Motion (PROM) - Elbow Extension | For the PROM all motions of wrist and elbow were measured from a defined neutral starting point position. The degrees of motion were added in the direction the wrist and elbow moved from the neutral starting position. The neutral starting position was the position of an upright standing/sitting person. The angle of the motion from the neutral starting position was measured in degrees using a goniometer. Angles were measured for the wrist with maximal dorsal extension, neutral position and maximal palmar flexion, and for the elbow with maximal extension, neutral position and maximal flexion. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Mean | Standard Error | degree | | baseline, week 4, week 12, follow up (between week 12 and week 20) | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Change From Baseline in Passive Range of Motion (PROM) - Wrist Maximum Flexion | For the PROM all motions of wrist and elbow were measured from a defined neutral starting point position. The degrees of motion were added in the direction the wrist and elbow moved from the neutral starting position. The neutral starting position was the position of an upright standing/sitting person. The angle of the motion from the neutral starting position was measured in degrees using a goniometer. Angles were measured for the wrist with maximal dorsal extension, neutral position and maximal palmar flexion, and for the elbow with maximal extension, neutral position and maximal flexion. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Mean | Standard Error | degree | | baseline, week 4, week 12, follow up (between week 12 and week 20) | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Change From Baseline in Passive Range of Motion (PROM) - Elbow Maximum Flexion | For the PROM all motions of wrist and elbow were measured from a defined neutral starting point position. The degrees of motion were added in the direction the wrist and elbow moved from the neutral starting position. The neutral starting position was the position of an upright standing/sitting person. The angle of the motion from the neutral starting position was measured in degrees using a goniometer. Angles were measured for the wrist with maximal dorsal extension, neutral position and maximal palmar flexion, and for the elbow with maximal extension, neutral position and maximal flexion. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Mean | Standard Error | degree | | baseline, week 4, week 12, follow up (between week 12 and week 20) | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Investigator's Global Assessment of Treatment Response (GATR) - Full Analysis Set | The investigator's global assessment of response to treatment were determined with the use of the Global Response Scale using the following scores: -4 = very marked worsening; -3 = marked worsening; -2 = moderate worsening; -1 = mild worsening; 0 = no change; +1 = mild improvement; +2 = moderate improvement; +3 = marked improvement; +4 = very marked improvement. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Mean | Standard Error | units on a scale | | week 4 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Patient's Global Assessment of Treatment Response (GATR) - Full Analysis Set | The patient's global assessment of response to treatment were determined with the use of the Global Response Scale using the following scores: -4 = very marked worsening; -3 = marked worsening; -2 = moderate worsening; -1 = mild worsening; 0 = no change; +1 = mild improvement; +2 = moderate improvement; +3 = marked improvement; +4 = very marked improvement. | | Posted | | Mean | Standard Error | units on a scale | | week 4 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Response Rates in Activity of Daily Living (Barthel Index) at Week 4 - Item Feeding | Response is defined as an improvement (increase) of at least one point in the Barthel Index from baseline visit. The Barthel Index was assessed for the items feeding, grooming, toilet use, bathing and dressing. Feeding: 0 = unable; 1 = needs help cutting, spreading butter etc.; 2 = independent; Grooming: 0 = needs help with personal care; 1 = independent face/hair/teeth/shaving; Toilet use: 1 = need some help, but could do something alone; 2 = independent; Bathing: 0 = dependent; 1 = independent; Dressing: 0 = dependent; 1 = needs help but could do about half unaided; 2 = independent. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | week 4 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Response Rates in Activity of Daily Living (Barthel Index) at Week 12 - Item Feeding | Response is defined as an improvement (increase) of at least one point in the Barthel Index from baseline visit. The Barthel Index was assessed for the items feeding, grooming, toilet use, bathing and dressing. Feeding: 0 = unable; 1 = needs help cutting, spreading butter etc.; 2 = independent; Grooming: 0 = needs help with personal care; 1 = independent face/hair/teeth/shaving; Toilet use: 1 = need some help, but could do something alone; 2 = independent; Bathing: 0 = dependent; 1 = independent; Dressing: 0 = dependent; 1 = needs help but could do about half unaided; 2 = independent. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | week 12 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Response Rates in Activity of Daily Living (Barthel Index) at Follow up - Item Feeding | Response is defined as an improvement (increase) of at least one point in the Barthel Index from baseline visit. The Barthel Index was assessed for the items feeding, grooming, toilet use, bathing and dressing. Feeding: 0 = unable; 1 = needs help cutting, spreading butter etc.; 2 = independent; Grooming: 0 = needs help with personal care; 1 = independent face/hair/teeth/shaving; Toilet use: 1 = need some help, but could do something alone; 2 = independent; Bathing: 0 = dependent; 1 = independent; Dressing: 0 = dependent; 1 = needs help but could do about half unaided; 2 = independent. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | follow up visit, between week 12 and week 20 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Response Rates in Activity of Daily Living (Barthel Index) at Week 4 - Item Grooming | Response is defined as an improvement (increase) of at least one point in the Barthel Index from baseline visit. The Barthel Index was assessed for the items feeding, grooming, toilet use, bathing and dressing. Feeding: 0 = unable; 1 = needs help cutting, spreading butter etc.; 2 = independent; Grooming: 0 = needs help with personal care; 1 = independent face/hair/teeth/shaving; Toilet use: 1 = need some help, but could do something alone; 2 = independent; Bathing: 0 = dependent; 1 = independent; Dressing: 0 = dependent; 1 = needs help but could do about half unaided; 2 = independent. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | week 4 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Response Rates in Activity of Daily Living (Barthel Index) at Week 12 - Item Grooming | Response is defined as an improvement (increase) of at least one point in the Barthel Index from baseline visit. The Barthel Index was assessed for the items feeding, grooming, toilet use, bathing and dressing. Feeding: 0 = unable; 1 = needs help cutting, spreading butter etc.; 2 = independent; Grooming: 0 = needs help with personal care; 1 = independent face/hair/teeth/shaving; Toilet use: 1 = need some help, but could do something alone; 2 = independent; Bathing: 0 = dependent; 1 = independent; Dressing: 0 = dependent; 1 = needs help but could do about half unaided; 2 = independent. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | week 12 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Response Rates in Activity of Daily Living (Barthel Index) at Follow up - Item Grooming | Response is defined as an improvement (increase) of at least one point in the Barthel Index from baseline visit. The Barthel Index was assessed for the items feeding, grooming, toilet use, bathing and dressing. Feeding: 0 = unable; 1 = needs help cutting, spreading butter etc.; 2 = independent; Grooming: 0 = needs help with personal care; 1 = independent face/hair/teeth/shaving; Toilet use: 1 = need some help, but could do something alone; 2 = independent; Bathing: 0 = dependent; 1 = independent; Dressing: 0 = dependent; 1 = needs help but could do about half unaided; 2 = independent. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | follow up visit, between week 12 and week 20 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Response Rates in Activity of Daily Living (Barthel Index) at Week 4 - Item Toilet Use | Response is defined as an improvement (increase) of at least one point in the Barthel Index from baseline visit. The Barthel Index was assessed for the items feeding, grooming, toilet use, bathing and dressing. Feeding: 0 = unable; 1 = needs help cutting, spreading butter etc.; 2 = independent; Grooming: 0 = needs help with personal care; 1 = independent face/hair/teeth/shaving; Toilet use: 1 = need some help, but could do something alone; 2 = independent; Bathing: 0 = dependent; 1 = independent; Dressing: 0 = dependent; 1 = needs help but could do about half unaided; 2 = independent. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | week 4 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Response Rates in Activity of Daily Living (Barthel Index) at Week 12 - Item Toilet Use | Response is defined as an improvement (increase) of at least one point in the Barthel Index from baseline visit. The Barthel Index was assessed for the items feeding, grooming, toilet use, bathing and dressing. Feeding: 0 = unable; 1 = needs help cutting, spreading butter etc.; 2 = independent; Grooming: 0 = needs help with personal care; 1 = independent face/hair/teeth/shaving; Toilet use: 1 = need some help, but could do something alone; 2 = independent; Bathing: 0 = dependent; 1 = independent; Dressing: 0 = dependent; 1 = needs help but could do about half unaided; 2 = independent. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | week 12 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Response Rates in Activity of Daily Living (Barthel Index) at Follow up - Item Toilet Use | Response is defined as an improvement (increase) of at least one point in the Barthel Index from baseline visit. The Barthel Index was assessed for the items feeding, grooming, toilet use, bathing and dressing. Feeding: 0 = unable; 1 = needs help cutting, spreading butter etc.; 2 = independent; Grooming: 0 = needs help with personal care; 1 = independent face/hair/teeth/shaving; Toilet use: 1 = need some help, but could do something alone; 2 = independent; Bathing: 0 = dependent; 1 = independent; Dressing: 0 = dependent; 1 = needs help but could do about half unaided; 2 = independent. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | follow up visit, between week 12 and week 20 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Response Rates in Activity of Daily Living (Barthel Index) at Week 4 - Item Bathing/Showering | Response is defined as an improvement (increase) of at least one point in the Barthel Index from baseline visit. The Barthel Index was assessed for the items feeding, grooming, toilet use, bathing and dressing. Feeding: 0 = unable; 1 = needs help cutting, spreading butter etc.; 2 = independent; Grooming: 0 = needs help with personal care; 1 = independent face/hair/teeth/shaving; Toilet use: 1 = need some help, but could do something alone; 2 = independent; Bathing: 0 = dependent; 1 = independent; Dressing: 0 = dependent; 1 = needs help but could do about half unaided; 2 = independent. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | week 4 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Response Rates in Activity of Daily Living (Barthel Index) at Week 12 - Item Bathing/Showering | Response is defined as an improvement (increase) of at least one point in the Barthel Index from baseline visit. The Barthel Index was assessed for the items feeding, grooming, toilet use, bathing and dressing. Feeding: 0 = unable; 1 = needs help cutting, spreading butter etc.; 2 = independent; Grooming: 0 = needs help with personal care; 1 = independent face/hair/teeth/shaving; Toilet use: 1 = need some help, but could do something alone; 2 = independent; Bathing: 0 = dependent; 1 = independent; Dressing: 0 = dependent; 1 = needs help but could do about half unaided; 2 = independent. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | week 12 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Response Rates in Activity of Daily Living (Barthel Index) at Follow up - Item Bathing/Showering | Response is defined as an improvement (increase) of at least one point in the Barthel Index from baseline visit. The Barthel Index was assessed for the items feeding, grooming, toilet use, bathing and dressing. Feeding: 0 = unable; 1 = needs help cutting, spreading butter etc.; 2 = independent; Grooming: 0 = needs help with personal care; 1 = independent face/hair/teeth/shaving; Toilet use: 1 = need some help, but could do something alone; 2 = independent; Bathing: 0 = dependent; 1 = independent; Dressing: 0 = dependent; 1 = needs help but could do about half unaided; 2 = independent. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | follow up visit, between week 12 and week 20 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Response Rates in Activity of Daily Living (Barthel Index) at Week 4 - Item Dressing | Response is defined as an improvement (increase) of at least one point in the Barthel Index from baseline visit. The Barthel Index was assessed for the items feeding, grooming, toilet use, bathing and dressing. Feeding: 0 = unable; 1 = needs help cutting, spreading butter etc.; 2 = independent; Grooming: 0 = needs help with personal care; 1 = independent face/hair/teeth/shaving; Toilet use: 1 = need some help, but could do something alone; 2 = independent; Bathing: 0 = dependent; 1 = independent; Dressing: 0 = dependent; 1 = needs help but could do about half unaided; 2 = independent. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | week 4 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Response Rates in Activity of Daily Living (Barthel Index) at Week 12 - Item Dressing | Response is defined as an improvement (increase) of at least one point in the Barthel Index from baseline visit. The Barthel Index was assessed for the items feeding, grooming, toilet use, bathing and dressing. Feeding: 0 = unable; 1 = needs help cutting, spreading butter etc.; 2 = independent; Grooming: 0 = needs help with personal care; 1 = independent face/hair/teeth/shaving; Toilet use: 1 = need some help, but could do something alone; 2 = independent; Bathing: 0 = dependent; 1 = independent; Dressing: 0 = dependent; 1 = needs help but could do about half unaided; 2 = independent. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | week 12 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |
| Secondary | Response Rates in Activity of Daily Living (Barthel Index) at Follow up - Item Dressing | Response is defined as an improvement (increase) of at least one point in the Barthel Index from baseline visit. The Barthel Index was assessed for the items feeding, grooming, toilet use, bathing and dressing. Feeding: 0 = unable; 1 = needs help cutting, spreading butter etc.; 2 = independent; Grooming: 0 = needs help with personal care; 1 = independent face/hair/teeth/shaving; Toilet use: 1 = need some help, but could do something alone; 2 = independent; Bathing: 0 = dependent; 1 = independent; Dressing: 0 = dependent; 1 = needs help but could do about half unaided; 2 = independent. | Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed. | Posted | | Number | | participants | | follow up visit, between week 12 and week 20 | | | | ID | Title | Description |
|---|
| OG000 | incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL | | | OG001 | incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL | |
| |